Anebulo Pharmaceuticals, Inc.
ANEB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | 0.26 | -0.08 | 0.23 |
| FCF Yield | -13.04% | -11.69% | -16.43% | -4.48% |
| EV / EBITDA | -4.02 | -8.48 | -4.05 | 19,234.12 |
| Quality | ||||
| ROIC | -77.37% | -217.94% | -110.00% | -45.34% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.75 | 0.99 | 0.83 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 21.52% | 16.44% | -78.09% | -11.62% |
| Safety | ||||
| Net Debt / EBITDA | 1.26 | 0.40 | 0.95 | -2,618.99 |
| Interest Coverage | -24.14 | -54.94 | 0.00 | -931.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |